Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03761914 · ClinicalTrials.gov registry record · Phase 1
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
A Phase 1 study, sponsored by Sellas Life Sciences Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT03761914: Completed Phase 1 study, sponsored by Sellas Life Sciences Group.
NCT03761914 is a Phase 1 study that has completed, run by Sellas Life Sciences Group. The registered enrollment target is 26 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (57% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03761914, a Phase 1 study, has completed, sponsored by Sellas Life Sciences Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
To evaluate the safety, tolerability, and anti-tumor activity of galinpepimut-S in combination with pembrolizumab in patients with selected advanced cancers.
Primary Outcome
Percentage of patients who have received at least one dose of pembrolizumab and have responded (and have completed imaging requirements). Best overall response is defined as the best overall visit response in the following order: CR, PR, SD, PD, or UE as measured by RECIST 1.1
Interventions
- BIOLOGICAL pembrolizumab
- BIOLOGICAL GM-CSF
- OTHER Montanide
- BIOLOGICAL galinpepimut-S
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2019-09-30 |
| Est. Completion | 2022-10-27 |
| Phase | Phase 1 |
What the finished NCT03761914 record still lists
NCT03761914 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (57% lower).
The record links to 0 conditions, and to 4 interventions - of which pembrolizumab is the first listed.
NCT03761914 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03761914 about?
NCT03761914 is a clinical study titled "Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers". To evaluate the safety, tolerability, and anti-tumor activity of galinpepimut-S in combination with pembrolizumab in patients with selected advanced cancers.
What is the current status of trial NCT03761914?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2019-09-30. Estimated completion is 2022-10-27.
What interventions are being tested in trial NCT03761914?
The interventions under investigation include: pembrolizumab (BIOLOGICAL), GM-CSF (BIOLOGICAL), Montanide (OTHER), galinpepimut-S (BIOLOGICAL).
Who is sponsoring clinical trial NCT03761914?
This trial is sponsored by Sellas Life Sciences Group, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03761914's enrollment target sits among peer trials
26 1482nd of 2000 higher than 506 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI